$0.81
+0.01 (+1.50%)
Open$0.81
Previous Close$0.80
Day High$0.82
Day Low$0.78
52W High$2.68
52W Low$1.00
Volume—
Avg Volume2.87M
Market Cap180.45M
P/E Ratio—
EPS$-0.12
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+2,708.8% upside
Current
$0.81
$0.81
Target
$22.81
$22.81
$15.42
$22.81 avg
$25.92
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 140.90M | 124.82M | 36.22M |
| Net Income | -18,363,329 | -14,641,208 | -2,507,722 |
| Profit Margin | -13.0% | -12.4% | -6.9% |
| EBITDA | -9,295,392 | -7,823,017 | -3,086,652 |
| Free Cash Flow | — | — | -2,753,402 |
| Rev Growth | +12.9% | +12.9% | +20.2% |
| Debt/Equity | 9.81 | 9.81 | 0.74 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.03 | -0.25% | 139.7 | 43.84B |